The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Mario Mandalà
Honoraria - Bristol-Myers Squibb/Sanofi; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Aventis
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
Research Funding - Novartis (Inst)
 
Pier Francesco Ferrucci
Expert Testimony - Delcath Systems
 
Massimo Guidoboni
Honoraria - Bristol-Myers Squibb; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre
Research Funding - MSD (Inst)
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Virginia Ferraresi
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Novartis
 
Ana Maria Arance
Consulting or Advisory Role - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - BMS (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Novartis; Pierre Fabre
 
Michele Guida
No Relationships to Disclose
 
Evaristo Maiello
No Relationships to Disclose
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Erika Richtig
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pierre Fabre (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
 
Maria Teresa Fierro
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Novartis
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Other Relationship - Avantis Medical Systems
 
Hildur Helgadottir
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - MSD; Novartis
 
Ignacio Melero Bermejo
Honoraria - Highlight Therapeutics; PharmaMar
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Bayer; BiolineRx; Boston Pharmaceuticals; Bristol-Myers Squibb; Catalym; crispr therapeutics; EMD Serono; F-star; Genmab; Genmab; Gossamer Bio; Lilly; Moderna Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; MSD; Noxxon Pharma; Numab; Pieris Pharmaceuticals; Roche/Genentech; SERVIER; Tusk Therapeutics; Tusk Therapeutics
Research Funding - Alligator Bioscience; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche/Genentech
 
Giuseppe Palmieri
Consulting or Advisory Role - Novartis; Pierre Fabre
 
Diana Giannarelli
No Relationships to Disclose
 
Antonio Maria Grimaldi
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis
Travel, Accommodations, Expenses - Novartis; Pierre Fabre
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Vanna Chiarion-Sileni
No Relationships to Disclose